1)The AGIS Investigators:The advanced glaucoma intervention study(AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:429-440, 2000
2)Takagi Y, Nakajima T, Shimazaki A et al:Pharmacological characteristics of AFP-168(tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 78:767-776, 2004
3)Kaback M, Geanon J, Katz G et al:Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Curr Med Res Opin 20:1341-1345, 2004
4)Hollo G, Vargha P, Kothy P:Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication. Curr Med Res Opin 21:1943-1948, 2005
5)Bournias TE, Lee D, Gross R et al:Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension. J Ocul Pharmacol Ther 19:193-203, 2003
6)Williams RD:Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 19:275-281, 2002
7)湖崎 淳・大谷伸一郎・鵜木一彦・他:トラボプロスト点眼液の臨床使用成績―眼表面への影響.あたらしい眼科 26:101-104,2009
8)岩切 亮・小林 博・小林かおり・他:多剤使用時におけるブナゾシンのラタノプロストへの併用効果.臨眼 58:359-362,2004
9)Heijl A, Leske C, Bengtsson B et al:Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120:1268-1279, 2002
10)桑山泰明・米虫節夫:0.0015%DE-085(タフルプロスト)の原発開放隅角緑内障または高眼圧症を対象とした0.005%ラタノプロストとの第Ⅲ相検証的試験.あたらしい眼科 25:1595-1602,2008